Findings

What do systematic reviews say?

4 questions · 4 findings · 1 reviews · Colorectal

No studies found 0 · 0%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 2 · 50%High 2 · 50%

Overall survival · people with metastatic CRC

Modern chemotherapy regimens probably leads to lower overall survival compared with 5‐flourouracil (moderate certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 0.69 [0.51, 0.94]
1 study · 167 participants
Moderate

Progression‐free survival · people with metastatic CRC

Modern chemotherapy regimens leads to lower progression‐free survival compared with 5‐flourouracil (high certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
HR 0.59 [0.49, 0.73]
2 studies · 470 participants
High

Tumour response · people with metastatic CRC

Modern chemotherapy regimens leads to higher overall tumour response compared with 5‐flourouracil (high certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 2.96 [1.66, 5.27]
3 studies · 866 participants
High

Severe adverse effects · people with metastatic CRC

Modern chemotherapy regimens probably leads to higher severe adverse effects compared with 5‐flourouracil (moderate certainty).

1 finding from 1 review

Second‐line systemic therapy for metastatic colorectal cancer 2017 · Cochrane Headline outcomes only
RR 1.39 [1.22, 1.58]
3 studies · 843 participants
Moderate